CN1964737B - 利用il-1拮抗剂治疗自身炎症性疾病的方法 - Google Patents

利用il-1拮抗剂治疗自身炎症性疾病的方法 Download PDF

Info

Publication number
CN1964737B
CN1964737B CN2005800182189A CN200580018218A CN1964737B CN 1964737 B CN1964737 B CN 1964737B CN 2005800182189 A CN2005800182189 A CN 2005800182189A CN 200580018218 A CN200580018218 A CN 200580018218A CN 1964737 B CN1964737 B CN 1964737B
Authority
CN
China
Prior art keywords
val
leu
ser
thr
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN2005800182189A
Other languages
English (en)
Chinese (zh)
Other versions
CN1964737A (zh
Inventor
S·梅利斯
M·卡罗
G·D·扬克普罗斯
J·帕帕佐普洛斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CN1964737A publication Critical patent/CN1964737A/zh
Application granted granted Critical
Publication of CN1964737B publication Critical patent/CN1964737B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN2005800182189A 2004-06-04 2005-06-03 利用il-1拮抗剂治疗自身炎症性疾病的方法 Expired - Lifetime CN1964737B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57702304P 2004-06-04 2004-06-04
US60/577,023 2004-06-04
PCT/US2005/019674 WO2005117945A1 (en) 2004-06-04 2005-06-03 Methods of using il-1 antagonists to treat autoinflammatory disease

Publications (2)

Publication Number Publication Date
CN1964737A CN1964737A (zh) 2007-05-16
CN1964737B true CN1964737B (zh) 2011-04-20

Family

ID=34972252

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800182189A Expired - Lifetime CN1964737B (zh) 2004-06-04 2005-06-03 利用il-1拮抗剂治疗自身炎症性疾病的方法

Country Status (9)

Country Link
US (4) US7459426B2 (cg-RX-API-DMAC7.html)
EP (1) EP1750746A1 (cg-RX-API-DMAC7.html)
JP (2) JP5022216B2 (cg-RX-API-DMAC7.html)
CN (1) CN1964737B (cg-RX-API-DMAC7.html)
AU (1) AU2005249570B2 (cg-RX-API-DMAC7.html)
CA (1) CA2568352C (cg-RX-API-DMAC7.html)
IL (1) IL179512A0 (cg-RX-API-DMAC7.html)
MX (2) MXPA06014126A (cg-RX-API-DMAC7.html)
WO (1) WO2005117945A1 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005249503B2 (en) * 2003-11-10 2011-08-25 Vertex Pharmaceuticals Incorporated ICE inhibitors for the treatment of autoinflammatory diseases
ES2523147T3 (es) * 2004-02-26 2014-11-21 Baylor Research Institute Composiciones y métodos para el tratamiento sistémico de la artritis
WO2006076673A2 (en) * 2005-01-14 2006-07-20 Regeneron Pharmaceuticals, Inc. Use of il-i antagonists to treat polymyalgia rheumatica and giant cell arteritis
WO2007050607A2 (en) * 2005-10-26 2007-05-03 Novartis Ag Novel use of il-1beta compounds
CN101378764A (zh) * 2005-12-09 2009-03-04 贝勒研究院 通过血液白细胞微阵列分析对系统性红斑狼疮的诊断、预后和疾病发展的监测
EP2124997B1 (en) * 2006-10-20 2012-08-08 Regeneron Pharmaceuticals, Inc. Use of il-1 antagonists to treat gout and pseudogout
US7632490B2 (en) 2006-10-20 2009-12-15 Regeneron Pharmaceuticals, Inc. Use of IL-1 antagonists to treat gout
JP5272735B2 (ja) * 2007-01-30 2013-08-28 国立大学法人 新潟大学 生物学的製剤
US20080227709A1 (en) * 2007-03-14 2008-09-18 Baylor Research Institute Gene expression in peripheral blood mononuclear cells from children with diabetes
KR102606597B1 (ko) 2007-05-29 2023-11-29 노파르티스 아게 항-ｉｌ-1-베타 치료법에 대한 신규 적응증
BR112012007137A2 (pt) 2009-09-30 2015-09-15 Harvard College metodos para modulacao da autofagia por meio da modulacao de produtos genicos inibidores da autofagia
PT2582391T (pt) 2010-06-18 2019-01-11 Xbiotech Inc Tratamento da artrite
CA2806438C (en) 2010-07-29 2021-04-13 Eleven Biotherapeutics, Inc. Chimeric il-1 receptor type i agonists and antagonists
CU23923B1 (es) * 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
HRP20191494T1 (hr) * 2012-03-31 2019-11-29 R Pharm Int Llc Pripravak derivat osteoprotegerina i njegova uporaba
CN103509100B (zh) * 2012-06-15 2017-10-27 上海百迈博制药有限公司 一种白细胞介素‑1受体拮抗剂突变体
WO2014035361A1 (en) * 2012-08-26 2014-03-06 R-PHARM, CJSC (Closed Joint Stock Company) IL-1β INHIBITOR COMPOSITION AND USE THEREOF
KR102236926B1 (ko) 2013-03-13 2021-04-06 세센 바이오, 아이엔씨. 안구 운반을 위한 키메릭 사이토카인 제제
JP2016520615A (ja) * 2013-05-31 2016-07-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． アルツハイマー病を処置するためのｉｌ−１アンタゴニストを使用する方法
HK1225742A1 (zh) * 2013-08-22 2017-09-15 Acceleron Pharma, Inc. TGF-β受体II型变体及其用途
WO2015147789A1 (en) * 2014-03-24 2015-10-01 R-Pharm Overseas, Inc. Human il 1-r1 derived inhibitor of il-1b
JP6565099B2 (ja) * 2015-09-18 2019-08-28 国立大学法人 長崎大学 家族性地中海熱のバイオマーカー
RU2022102624A (ru) * 2015-10-01 2022-03-10 Хит Байолоджикс, Инк. Композиции и способы для соединения внеклеточных доменов типа i и типа ii в качестве гетерологичных химерных белков
KR20180134880A (ko) * 2016-03-09 2018-12-19 슈 생-쥐스땡 주산기 이환율 및/또는 사망률을 감소시키는 방법
EP3582813A4 (en) * 2017-02-16 2020-12-30 XBiotech, Inc TREATMENT OF SUPPURATIVE HIDRADENITIS
BR112019020373A2 (pt) * 2017-04-03 2020-04-28 Wisconsin Alumni Research Foundation micropartículas revestidas com minerais para liberação sustentada de moléculas biologicamente ativas
JP2022524178A (ja) * 2019-01-07 2022-04-28 セルリス パルティシパソエス リミターダ タンデム受容体ｃａｒにおける二重特異性と腫瘍マイクロ環境を変調する方法
WO2021089782A1 (en) * 2019-11-07 2021-05-14 Inflazome Limited Treatment of autoinflammatory disorders
JP7072260B2 (ja) * 2019-12-27 2022-05-20 国立大学法人愛媛大学 マックル・ウェルズ症候群の治療用医薬組成物
WO2021184128A1 (en) * 2020-03-20 2021-09-23 Institut De Cardiologie De Montreal Methods of treating a coronavirus infection using colchicine
US20230210792A1 (en) * 2020-06-05 2023-07-06 Aristea Therapeutics, Inc. Use of a combination of colchicine and a cxcr-2 inhibitors for the treatment or prevention of familial mediterranean fever (fmf) and flare-ups thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030143697A1 (en) * 1998-09-25 2003-07-31 Neil Stahl Receptor based antagonists and methods of making and using

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
AU2001259758A1 (en) * 2000-05-12 2001-11-26 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
NZ538569A (en) * 2002-09-06 2009-02-28 Amgen Inc Therapeutic human anti-IL-1R1 monoclonal antibody
US20050129685A1 (en) * 2003-09-18 2005-06-16 Jingtai Cao Use of IL-1 blockers to prevent corneal inflammation and neovascularization

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030143697A1 (en) * 1998-09-25 2003-07-31 Neil Stahl Receptor based antagonists and methods of making and using

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ECONOMIDES A N ET AL.CYTOKINE TRAPS:MULTI-COMPONENT,HIGH-AFFINITYBOLOCKERS OF CYTOKNE ACTION.NATURE MEDICINE9 1.2003,9(1),47-52. *
ECONOMIDESANETAL.CYTOKINETRAPS:MULTI-COMPONENT HIGH-AFFINITYBOLOCKERS OF CYTOKNE ACTION.NATURE MEDICINE9 1.2003
HAWKINS PHILIP N ET AL.SPECTRUM OF CLINICAL FEATUREAS INMUCKLE-WELLS SYNDDOME AND RESPONSE TOANAKINRA.ARTHRITIS AND RHEUMATISM50 2.2004,50(2),607-612.
HAWKINS PHILIP N ET AL.SPECTRUM OF CLINICAL FEATUREAS INMUCKLE-WELLS SYNDDOME AND RESPONSE TOANAKINRA.ARTHRITIS AND RHEUMATISM50 2.2004,50(2),607-612. *

Also Published As

Publication number Publication date
IL179512A0 (en) 2007-05-15
JP2012111768A (ja) 2012-06-14
US7459426B2 (en) 2008-12-02
WO2005117945A1 (en) 2005-12-15
MX344967B (es) 2017-01-12
CA2568352A1 (en) 2005-12-15
EP1750746A1 (en) 2007-02-14
US8414876B2 (en) 2013-04-09
HK1100837A1 (en) 2007-09-28
MXPA06014126A (es) 2007-07-18
US20050272655A1 (en) 2005-12-08
JP2008501716A (ja) 2008-01-24
US20090156492A1 (en) 2009-06-18
US20110318342A1 (en) 2011-12-29
CN1964737A (zh) 2007-05-16
AU2005249570B2 (en) 2011-06-16
AU2005249570A1 (en) 2005-12-15
US20110311537A1 (en) 2011-12-22
CA2568352C (en) 2011-09-13
JP5022216B2 (ja) 2012-09-12

Similar Documents

Publication Publication Date Title
CN1964737B (zh) 利用il-1拮抗剂治疗自身炎症性疾病的方法
US20040224893A1 (en) Methods of using IL-1 antagonists to treat neointimal hyperplasia
CA2502385C (en) Il-1 receptor based antagonists and methods of making and using
CN101528252B (zh) Il-1拮抗剂在治疗痛风中的应用
KR102424590B1 (ko) 미오스타틴에 결합하는 피브로넥틴 기반 스캐폴드 도메인 단백질
CN101014617B (zh) Il-1拮抗剂制剂
KR101682496B1 (ko) 혈관형성 유도인자를 길항하는 융합단백질 및 그 용도
KR101805201B1 (ko) Ｂｍｐ-ａｌｋ3 길항제 및 골 성장을 촉진시키는 사용되는 이의 용도
KR20140091651A (ko) 항-혈관 신생 항체-스캐폴드 및 가용성 수용체를 분비하는 세포주 및 이의 용도
KR20070057789A (ko) 인터루킨-21 수용체 활성의 상쇄
CN107969127B (zh) Apoa-1融合多肽及相关组合物和方法
KR20160086819A (ko) 캡슐화 세포 요법 카트리지
KR102461210B1 (ko) Uti 융합 단백질
CN113637084B (zh) 生物大分子靶向特异性补体抑制剂及其制备方法与应用
KR102162934B1 (ko) Lrg1 당단백질을 포함하는 융합 단백질을 함유하는 발기부전, 허혈성 질환 또는 말초 신경질환의 예방 또는 치료용 조성물
HK1100837B (en) Methods of using il-1 antagonists to treat autoinflammatory disease
HK1132925B (en) Use of il-1 antagonists to treat gout
HK1132925A (en) Use of il-1 antagonists to treat gout
CN101575379A (zh) 可溶性vegfr双功能融合受体、其制备方法及用途
HK1105421B (en) Il-1 antagonist formulations
Wang et al. Retrovirus-mediated delivery of an IL-4 receptor antagonist inhibits allergic responses in a murine model of asthma
HK40053193A (en) Biological macromolecular target-specific complement inhibitor, preparation method thereof, and application thereof
KR20240035445A (ko) Actrii 단백질 및 이의 용도

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1100837

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1100837

Country of ref document: HK

EE01 Entry into force of recordation of patent licensing contract
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20070516

Assignee: HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL Co.,Ltd.

Assignor: Kiniksa Pharmaceuticals, Ltd.

Contract record no.: X2023990000448

Denomination of invention: Method of using IL-1 antagonists to treat autoimmune inflammatory diseases

Granted publication date: 20110420

License type: Exclusive License

Record date: 20230428

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20110420